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ARTICLE OPEN
p53 isoforms differentially impact on the POLι dependent DNA
damage tolerance pathway
Yitian Guo 1, Melanie Rall-Scharpf 1, Jean-Christophe Bourdon 2, Lisa Wiesmüller 1,3✉ and Stephanie Biber 1,3✉
© The Author(s) 2021
The recently discovered p53-dependent DNA damage tolerance (DDT) pathway relies on its biochemical activities in DNA-binding,
oligomerization, as well as complex formation with the translesion synthesis (TLS) polymerase iota (POLι). These p53-POLι
complexes slow down nascent DNA synthesis for safe, homology-directed bypass of DNA replication barriers. In this study, we
demonstrate that the alternative p53-isoforms p53β, p53γ, Δ40p53α, Δ133p53α, and Δ160p53α differentially affect this p53-POLι-
dependent DDT pathway originally described for canonical p53α. We show that the C-terminal isoforms p53β and p53γ, comprising
a truncated oligomerization domain (OD), bind PCNA. Conversely, N-terminally truncated isoforms have a reduced capacity to
engage in this interaction. Regardless of the specific loss of biochemical activities required for this DDT pathway, all alternative
isoforms were impaired in promoting POLι recruitment to PCNA in the chromatin and in decelerating DNA replication under
conditions of enforced replication stress after Mitomycin C (MMC) treatment. Consistent with this, all alternative p53-isoforms no
longer stimulated recombination, i.e., bypass of endogenous replication barriers. Different from the other isoforms, Δ133p53α and
Δ160p53α caused a severe DNA replication problem, namely fork stalling even in untreated cells. Co-expression of each alternative
p53-isoform together with p53α exacerbated the DDT pathway defects, unveiling impaired POLι recruitment and replication
deceleration already under unperturbed conditions. Such an inhibitory effect on p53α was particularly pronounced in cells co-
expressing Δ133p53α or Δ160p53α. Notably, this effect became evident after the expression of the isoforms in tumor cells, as well
as after the knockdown of endogenous isoforms in human hematopoietic stem and progenitor cells. In summary, mimicking the
situation found to be associated with many cancer types and stem cells, i.e., co-expression of alternative p53-isoforms with p53α,
carved out interference with p53α functions in the p53-POLι-dependent DDT pathway.
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INTRODUCTION
Already in the nineties, shortly after p53 was recognized to be a
tumor suppressor [1, 2], it became clear that it is a key player in
the protection of the genome integrity [3]. Simultaneously, with
the discovery of p53′s canonical functions in transcriptionally
activating cell cycle-regulatory and pro-apoptotic genes through
sequence-specific DNA-binding [4–7], non-canonical functions of
p53 in DNA repair, recombination, and replication, not requiring
its transcriptional activity, emerged [8–14]. After more than 25
years of research, it came as a surprise when twelve TP53-isoforms
were identified, which are generated by the use of different
promoters, alternative splicing, and the internal ribosome entry
site [15, 16]. TP53 gene products other than the canonical p53α
lack N- and C-terminal domains of the human protein with well-
defined biochemical functions like the first transcriptional
transactivation domain (TAD1, amino acids [aa] 1 to 39 in p53α)
in Δ40p53α (Fig. 1A). These alternative p53-isoforms were then
found to be differentially expressed in normal and cancer tissues,
revealing pro-survival features of N-terminally truncated Δ133p53
and Δ160p53 in a p53α-dependent and -independent manner
[15]. Therefore, co-expression of alternative p53-isoforms provides
an additional mechanism to modulate p53α´s tumor suppressor
functions beyond TP53 gene mutations mostly affecting the DNA-
binding domain (DBD) [17].
While the canonical activities of p53-isoforms have been
investigated quite intensively [18], non-canonical functions in
stabilizing the genome have remained largely obscure. Recently,
we discovered that p53α, via interactions with proliferating cell
nuclear antigen (PCNA) and the translesion synthesis (TLS)
polymerase iota (POLι), regulates a homology-directed DDT-
pathway [19, 20]. This p53-POLι-dependent DDT-pathway serves
to bypass barriers during DNA replication and may confer a pro-
survival effect to stem cells from which, however, cancer stem
cells also benefit [19–22]. In this study, we analyzed the role of the
p53-isoforms p53β, p53γ, Δ40p53α, Δ133p53α, and Δ160p53α in
this p53-POLι-dependent DDT through the analyses of replication-
associated recombination, DNA replication dynamics, and key
protein interactions. We provide evidence that these alternative
p53-isoforms differentially lost biochemical functions in the
homology-directed resolution of replication barriers. When co-
expressed with p53α, thereby mimicking their status in cancer
tissues, alternative p53-isoforms block the p53-POLι-dependent
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DDT-pathway which unlocks faster and likely more mutagenic
bypass mechanisms.
RESULTS
The p53-isoforms p53β, p53γ, Δ40p53α, Δ133p53α, and
Δ160p53α have lost p53α′s activity to stimulate replication-
associated recombination
Our previous work demonstrated that p53α bypasses replication
obstacles via a homology-directed DDT-pathway which can be
detected by measurements of spontaneous, i.e., replication-
associated recombination events [19]. To investigate the role of
N-terminally truncated p53-isoforms (ΔN) Δ40p53α, Δ133p53α,
and Δ160p53α, as well as C-terminally, modified isoforms p53β
and p53γ (Fig. 1A; [23]), we analyzed recombination on
chromosomally integrated EGFP-substrate (Supplementary Fig.
S1A). p53α expression in the p53α-negative K562(HR-EGFP/3′EGFP)
reporter cells [19, 24–26] stimulated recombination 3.7-fold
compared to control samples (ctrl) (Fig. 1B, C). To the contrary,
expression of all other p53-isoforms did not alter recombination
frequencies compared to ctrl (Fig. 1B, C). Conditions of protein
expression were based on preceding titration experiments to
ensure comparable p53 levels as shown in the right panels of Fig.
1B, C. Notably, while p53α-expressing cells stimulated p21 and to
a lesser extent also MDM2 expression in K562 cells, alternative
p53-isoforms failed to induce p21 (Fig. 1B, C). In conclusion, both
N-terminally truncated and C-terminally modified p53-isoforms
were impaired in activating homology-directed DDT.
p53-isoforms differentially affect DNA replication dynamics
after mock- and MMC-treatment
Activation of homology-directed DDT by p53α has been linked to
a replication slow-down detectable by DNA fiber spreading assay
[19, 20]. Accordingly, we investigated the effect of the p53-
isoforms on DNA replication speed in K562 cells (Fig. 2). After
sequential incubation with 5-Chloro-2-deoxyuridine (CldU) and 5-
iodo-2-deoxyuridine (IdU) (experimental overview and represen-
tative fibers in left panels of Fig. 2), we monitored a similar
shortening of the DNA track lengths after expression of p53α or
p53β compared to ctrl after mock-treatment (Fig. 2A). Expression
of p53γ generated intermediate track lengths. After treatment
with the replication stress-inducing agent MMC only p53α, but not
p53β or p53γ, decreased track lengths (Fig. 2B). To investigate, if
deceleration of DNA replication was associated with stalling, we
Fig. 1 Analysis of the p53 isoforms p53α, p53β, p53γ, Δ40p53α, Δ133p53α, and Δ160p53α in replication-associated recombination. K562
(HR-EGFP/3′-EGFP) cells were transfected with 10 µg expression plasmid for p53α and corresponding amounts for p53β, p53γ, Δ40p53α,
Δ133p53α, Δ160p53α or empty vector (EV) in controls (ctrl) as indicated in the graphs. Seventy-two hours after transfection FACS analysis (left
panels of B, C) and protein harvesting (right panels of B, C) were performed. Recombination (rec.) fold changes were analyzed flow
cytometrically by quantification of EGFP-positive cells among living cells. Mean values from p53α-expressing cells were set to 1 (absolute
mean frequencies: 4*10−5). Data were collected from ≥18 individual measurements each. For graphic presentation, calculation of SEM and
statistically significant differences via Kruskal-Wallis test followed by two-tailed Mann−Whitney U test GraphPadPrism8.4 software was used. #
indicates a statistically significant difference between ctrl and the respective p53-isoform data. ****(# # # #) P < 0.0001. Quantification of
protein levels was carried out using ImageLab software, normalized to β-actin, and indicated above the representative immunoblot.
A Schematic overview of different domains of p53 isoforms. p53α (highlighted in black) consists of transactivation domain I (TAD I),
transactivation domain II (TAD II), proline-rich domain (PRD), DNA-binding domain, hinge domain (HD), oligomerization domain (OD),
C-terminal domain (CTD) while parts of the other p53-isoforms are replaced by other sequences or missing. Note that the color code in the
scheme was used in the subsequent graphs. B Role of p53β and p53γ in replication-associated recombination. Left panel shows
Recombination (Rec.) fold changes. Right panel shows representative Western Blot analysis of the indicated p53 isoforms. β-Actin served as a
loading control. C Role of p53α, Δ40p53α, Δ133p53α, and Δ160p53α in replication-associated recombination. Left panel shows Rec. fold
changes. Right panel shows representative Western Blot analysis of the indicated p53 isoforms. β-Actin served as loading control.
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measured the ratio of two IdU track lengths emanating from the
same CldU track (fork asymmetry [FA]; graphic presentations
shown on top of right panels in Fig. 2) [19, 27]. While MMC-
treatment increased FA, no further changes were seen after p53α,
p53β, or p53γ expression (Fig. 2A, B).
Next, we performed DNA fiber spreading assays after the
expression of p53α- or ΔN-isoforms. Similar as with the C-terminal
isoforms, we observed differences between mock- and MMC-
treatments: after mock-treatment expression of p53α and all ΔN-
isoforms decelerated DNA replication (Fig. 2C). Interestingly, FA
analysis revealed increased values in Δ133p53α- and Δ160p53α-
expressing cells compared to all other samples. After MMC-
treatment only p53α shortened DNA track lengths, while FA values
did not differ between the samples (Fig. 2D). Hence, whereas track
shortening in Δ133p53α and Δ160p53α-expressing cells was
associated with stalling after mock-treatment, shortening in
Y. Guo et al.
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p53α or Δ40p53α-expressing cells did not, compatible with a role
in continuous deceleration of nascent DNA synthesis. As such a
role of p53α was demonstrated to depend on POLι [19], we
examined POLι expression levels in K562 cells after mock- and
MMC-treatment. However, no significant differences were
observed (Supplementary Fig. S1B, C).
To examine nascent DNA synthesis as a function of the p53-
isoforms in another p53-negative cell type, we engaged Saos-2
(Supplementary Fig. S2). Here, p21 and MDM2 were detectable in
p53α-expressing cells only (Supplementary Fig. S2A). Results from
DNA fiber spreading assays were consistent with the results in
K562 except that in mock-treated cells p53γ was not only
intermediate, but fully functional in track shortening (Supplemen-
tary Fig. S2B) and Δ40p53 only partially functional (Supplementary
Fig. S2D).
Since the p53 targets p21 and MDM2 were reported to play
roles in the regulation of replication [28–30], we expressed
exogenous p21 and MDM2 in cells with representative C-terminal
and ΔN-isoforms. DNA fiber spreading analyses revealed that
these proteins did not reconstitute the replication track short-
ening phenotype of p53α in p53γ, Δ133p53α or Δ160p53α-
expressing cells treated with MMC (Supplementary Fig. S3). From
this, it is unlikely that changes in p21 and MDM2 expression
explain dysfunction of p53-isoforms in the p53-POLι DDT-
pathway.
Taken together, C-terminal and ΔN-isoforms of p53 show at
least partial function after mock- but full loss-of-function after
MMC-treatment in track shortening. Therefore, failure to decele-
rate replication under conditions of enforced replication stress
mirrors their defect in recombination stimulation (Fig. 1B, C)
indicating loss of key biochemical activities in the homology-
directed DDT-pathway.
C-terminal and ΔN-isoforms no longer promote ternary p53-
POLι-PCNA complex formation in MMC-treated cells
Our previous work demonstrated that POLι forms a complex with
p53 and PCNA and that this p53-POLι idling complex is required to
slow down replication [19, 20]. Therefore, we investigated the
subnuclear distribution of POLι and PCNA as well as their
association after the expression of different p53-isoforms in
K562 (Fig. 3). In mock-treated cells, we observed increased
accumulation of POLι-foci in all p53-expressing cells except for
Δ160p53α and of PCNA-foci except for p53α and Δ40p53α (Fig.
3A, B, D, E). Moreover, we observed a 2- to 4-fold increase of co-
localized POLι-PCNA-foci in all p53-expressing cells (Fig. 3C, F).
However, after MMC-treatment, increased numbers of POLι- as
well as co-localized POLι-PCNA-foci seen after p53α expression
was lost with all other p53-isoforms (Fig. 3A, C, D, F). This defect
was similarly seen regarding PCNA-foci in cells expressing
C-terminal p53-isoforms but not ΔN-isoforms (Fig. 3B, E). Specific
POLι detection was verified by POLι-silencing (Supplementary Fig.
S4). Moreover, we analyzed the percentages of MMC-treated K562
cells in different cell cycle phases and in apoptosis as indicated by
a sub-G1 content (Supplementary Fig. S5). This analysis did not
reveal significant differences in cells expressing different p53-
isoforms, though a trend of enhanced apoptosis was noticed in
p53α-expressing cells.
Next, we investigated physical interactions between p53, POLι,
and PCNA in co-immunoprecipitation studies after the preparation
of crosslinked chromatin. After pull-down of POLι, we detected
less than half of the input levels of p53β and p53γ in the co-
precipitate as compared with p53α (Fig. 4A). In PCNA co-
precipitates p53β and p53γ levels were not reduced. After pull-
down of p53α without crosslink, we also observed an interaction
with PCNA, as reported before [19]. However, PCNA band
intensities were reduced by 50−90% relative to input in co-
precipitates of the N-terminally truncated p53-isoforms (Fig. 4B).
Previously, we showed that p53α binds POLι via its N-terminus
[20]. Consistently, p53α but not Δ40p53α co-immunoprecipitated
POLι (Supplementary Fig. S6). Altogether, all alternative p53-
isoforms are defective in supporting the formation of POLι-PCNA-
complexes after MMC-treatment in situ. In co-precipitation
experiments, POLι-p53-complex formation is defective in cells
expressing any alternative isoform and PCNA−p53 interactions
are compromised in cells expressing ΔN-isoforms of p53.
Regulation of PCNA ubiquitination by p53-isoforms
Deceleration of nascent DNA synthesis in the p53-POLι DDT-
pathway buys time for the cell to polyubiquitinate PCNA and
recruitment of helicase-like transcription factor (HLTF) and Zinc
Finger Ran-Binding Domain-Containing Protein 3 (ZRANB3) to
bypass the replication barrier [19, 20]. Western Blot analysis
revealed a statistically significant 1.5- to 1.8-fold increase (P ≤
0.0156) of PCNA-monoubiquitination in mock-treated cells after
expression of any of the p53-isoforms (Fig. 5A–C). PCNA-
polyubiquitination showed a similar pattern (Fig. 5A–C), but the
statistical significance of the increase in polyubiquitination was
reached only with p53α-expressing cells (P= 0.0156). After MMC-
treatment we detected reduced levels of mono- and polyubiqui-
tinated PCNA in cells expressing C-terminal or ΔN-isoforms as
compared with p53α (Fig. 5A, B, D), which reached statistical
significance (P= 0.0078) with p53β and p53γ samples (Fig. 5D).
We conclude that alternative p53-isoforms are compromised in
supporting PCNA-ubiquitination after MMC-treatment.
Subsequently, we silenced HLTF and ZRANB3 to investigate a
potential impact on PCNA-ubiquitination (Supplementary Fig. S7)
as both proteins were found to exert critical roles in the POLι DDT-
pathway, most likely mediating PCNA-polyubiquitination and fork
reversal, respectively [19]. In MMC-treated cells expressing p53α,
we found that knockdown of HLTF reduced PCNA-poly- but not
-monoubiquitination (Supplementary Fig. S7A, C, E), while knock-
down of ZRANB3 had no effect (Supplementary. Fig. S7B, D, F). In
MMC-treated cells, neither HLTF nor ZRANB3 affected PCNA-
polyubiquitination after p53γ or Δ133p53α expression strengthen-
ing the notion of their reduced capacity to stimulate PCNA-
polyubiquitination.
Fig. 2 p53α and its isoforms modulate nascent DNA synthesis. K562 cells were transfected with expression plasmids for p53α, alternative
p53 isoforms [A, B p53β, p53γ or C, D Δ40p53α, Δ133p53α, Δ160p53α] or EV in controls (ctrl). Forty-eight hours after transfection DNA fiber
spreading assay was performed. Graphic overviews in the left panel show the experimental outline and representative fibers. Cells were
subsequently incubated with 5-chloro-2′-deoxyuridine (CldU, 20 µM) and 5-iodo-2′-deoxyuridine (IdU, 200 µM) for 20min. During IdU-
incorporation cells were either mock-treated (A, C) or treated with 3 µM MMC (B, D). Both, CldU- and IdU-tracks were measured but for clarity
graphic presentations in the middle panel focus on IdU-tracks in ongoing forks (≥361 to ≥423 fibers in two independent biological
experiments). Right panels show the graphic presentation of FA with the respective schematic overview on top. DNA fibers were reanalyzed
comparing track lengths of IdU incorporation (red) originating from the same CldU track (green). Graphs represent ≥66 to ≥121 fibers from
two independent biological experiments. For graphic presentation, calculation of SEM, and statistically significant differences
GraphPadPrism8.4 software was used. Statistically significant differences among groups were calculated by Dunn’s multiple comparisons
test. # indicates a statistically significant difference between ctrl and the respective p53 isoform. (#)P < 0.05, ***P < 0.001, ****(# # # #), P <
0.0001 (scale bar: 5 µm).
Y. Guo et al.
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Fig. 3 Effect of the p53 isoforms on the subcellular distribution and association of POLι and PCNA. K562 cells were transfected with
expression plasmids for p53α, alternative p53 isoforms [A−C p53β, p53γ, D−F Δ40p53α, Δ133p53α, Δ160p53α] or EV in controls (ctrl). Forty-
eight hours after transfection, cells were mock- or MMC-treated (3 μM, 45min, 3 h release) and processed for immunostaining to visualize POLι
and PCNA foci as well as their co-localization. At least 100 nuclei were scored in ≥ two independent experiments. Mean values for p53α
expressing cells after MMC-treatment were set to 1 [on average 103 POLι (A, D), 133 PCNA (B, E), and 15 POLι-PCNA co-localized (C, F) foci/
nucleus]. For graphic presentation, calculation of SEM and statistically significant differences via Dunn’s multiple comparisons test
GraphPadPrism8.4 software was used. Representative images of MMC-treated samples are shown in (G). The experiments shown in (A) and
(D), (B) and (E) as well as (C) and (F) were performed together (values of ctrl and p53α are identical but separated in different panels for clarity)
and with the experiments presented in Fig. 6. *(#)P < 0.05, **(# #)P < 0.01, ***(# # #)P < 0.001, ****(# # # #), P < 0.0001 (scale bar: 5 µm).
Y. Guo et al.
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Alternative p53-isoforms exert an inhibitory effect on p53α in
the p53-POLι DDT-pathway
Previous reports described the inactivation of p53α by hetero-
oligomerization with alternative p53-isoforms [31–33]. Conse-
quently, we were interested in how co-expression of p53α with
the different p53-isoforms will affect the p53-POLι-dependent
DDT. In mock-treated cells replication slow-down was observed
after expression of p53α at a level of 50% (p53α plus empty vector,
p53α+ EV) and 100% (p53α+ p53α) versus ctrl, but lost after co-
expression (50%:50%) of p53α with one of the alternative isoforms
(Fig. 6A, F). After MMC-treatment we observed replication
deceleration in p53α+ p53α but not in p53α+ p53γ, p53α+
Δ40p53α, p53α+ Δ133p53α or p53α+ Δ160p53α samples versus
ctrl and an intermediate phenotype in p53α+ p53β samples (Fig.
6B). Importantly, comparing track lengths in samples co-
transfected with p53α+ alternative isoforms versus p53α+ p53α
provided evidence for loss-of-function, i.e., loss of the track
shortening function in all isoforms independently of treatment
(Fig. 6A, B).
Notably, a 50% expression level of p53α in p53α+ EV samples
was sufficient to decelerate replication versus ctrl in unperturbed
but not in MMC-treated cells (compare p53α+ EV with p53α+
p53α in Fig. 6A, B). Most interestingly, when comparing p53α+ EV
samples with samples co-transfected with p53α+ alternative
isoforms, we found longer tracks in p53α+ p53β, p53α+
Δ133p53α, and p53α+ Δ160p53α samples after mock-treatment
and in p53α+ Δ40p53α, p53α+ Δ133p53α, and p53α+
Δ160p53α samples after MMC-treatment. These observations
suggested an inhibitory effect, which was most pronounced in
p53α+ Δ133p53α and p53α+ Δ160p53α samples.
Strikingly, we obtained almost the same results in Saos-2-cells:
Co-expression of each alternative p53-isoform did not decelerate
nascent DNA synthesis as seen in p53α+ p53α samples versus ctrl
independently of treatment, supporting the loss-of-function
concept (Supplementary Fig. S8A, B). Moreover, compared with
p53α+ EV longer tracks were measured in p53α+ Δ133p53α
mock-treated cells and p53α+ p53β, p53α+ Δ133p53α, and
p53α+ Δ160p53α MMC-treated cells. These Saos-2 data strength-
ened the concept of an inhibitory effect of the alternative p53-
isoform Δ133p53α in particular.
Next, we also investigated the subnuclear distribution of POLι
and PCNA, as well as their co-localization after co-expression of
p53α and alternative isoforms (Fig. 6C−E). Both, after mock- and
MMC-treatment, co-expression of p53α together with any alter-
native p53-isoform reduced accumulation of POLι and POLι-PCNA
colocalizing foci observed after expression of p53α alone (Fig. 6C,
E). It also abrogated p53α-mediated PCNA-foci accumulation after
MMC-treatment in p53α+ p53γ, p53α+ Δ40p53α, and p53α+
Δ133p53α samples (Fig. 6D). Notably, p53α+ p53β co-expression
causing intermediate DNA track lengths (Fig. 6B) also showed
intermediate enhancement of POLι-PCNA-co-localization after
MMC-treatment (Fig. 6E). Altogether, co-expression of alternative
isoforms blocked p53α-mediated recruitment of POLι into PCNA-
complexes and consequently slow-down of DNA replication,
which was still observed in mock-treated cells expressing
individual isoforms. In conclusion, co-expression of p53-isoforms
compromises the p53-POLι DDT not only via loss-of-function but
also via inhibitory effects.
To test the influence of endogenously expressed p53-isoforms,
we performed silencing experiments engaging siRNA targeting
either all p53 isoforms or siRNA targeting Δ133p53α (and
Δ160p53α), i.e., the isoform most robustly affecting DNA replica-
tion speed in the presence of p53α (Fig. 6A, B and Supplementary
Fig. S8A, B). We chose U2OS cells, as well as primary
hematopoietic stem and progenitor cells (HSPCs) derived from
human cord blood, as both carry wild-type TP53 and express p53α
Fig. 4 p53 isoforms differently interact with PCNA and POLι. K562 cells were transfected with expression plasmids for p53α, alternative p53
isoforms [A p53β, p53γ, B Δ40p53α, Δ133p53α, Δ160p53α] or EV in controls (ctrl). Forty-eight hours after transfection, cells were harvested for
immunoprecipitations (IP) after preparation of crosslinked chromatin (A) or without crosslinked chromatin preparation (B). For the pull-downs
of PCNA (A) anti-PCNA antibody (mouse, ab29, abcam, Cambridge, UK) or control Mouse IgG (Santa Cruz, Dallas, Texas, USA), for the pull-
downs of POLι (A) POLι-antibody (rabbit, A301-304A, Bethyl, Montgomery, USA) or Rabbit IgG were used. For the pull-down of p53 (B) a mix of
anti-p53(DO11) (mouse, MCA1704, BioRad Laboratories, München, Germany) and anti-p53(Pab421) (mouse, OP03, Calbiochem, Darmstadt,
Germany) or control Mouse IgG were used. Subsequent immunoblotting relied on anti-POLι (rabbit, A301-304A, Bethyl, Montgomery, USA),
anti-p53(DO1) (mouse, mAb, 554293, BD, Biosciences, Franklin Lakes, New Jersey, USA) in (A), anti-p53(DO11) (mouse, GTX75258, Genetex,
Irvine California, USA), anti-p53 (PAb421, rabbit, ab245685, Abcam Cambridge, UK), anti-PCNA (mouse, ab29, abcam, Cambridge, UK) in (B) and
light chain-specific peroxidase-coupled secondary antibody. *, asterisks mark bands possibly stemming from proteolytic cleavage of the p53-
isoform. Quantification of band intensities of co-precipitated proteins relative to their input is indicated. Representative Western blots from
three to four experiments are shown.
Y. Guo et al.
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and Δ133p53α (Fig. 7A, B). When performing DNA fiber spreading
assays, we found that DNA replication was accelerated both in
mock- and MMC-treated U2OS cells and HSPCs after silencing all
p53-isoforms (Fig. 7A, B). Selective knockdown of Δ133p53/
Δ160p53 (siΔ133p53) caused replication slowing in MMC-treated
HSPCs (Fig. 7B), matching lack of replication deceleration after
ectopic expression of Δ133p53α or Δ160p53α as compared to
p53α in MMC-treated K562 cells (Fig. 2D). For comparison,
replication track lengths were unaffected by siΔ133p53 in U2OS
cells, most likely due to a lower Δ133p53α/p53α ratio as compared
to HSPCs as deduced from the exposure times necessary to detect
p53α and Δ133p53α in immunoblots (Fig. 7A, B). Altogether, the
data in HSPCs confirmed an antagonistic role of endogenous
Δ133p53 towards the DNA replication decelerating role of p53α.
DISCUSSION
In this study, we provide evidence that both C-terminal and ΔN-
isoforms show loss of the p53α-specific functions in the p53-
POLι-dependent DDT-pathway [19, 20]. Underscoring the
biological relevance, we find interference of alternative p53-
isoforms, particularly of Δ133p53α and Δ160p53α, with p53α′s
functions in DNA replication both in human tumor and
stem cells.
Fig. 5 Altered PCNA ubiquitination after expression of p53α or alternative isoforms. K562 cells were transfected with expression plasmids
for p53α, alternative p53 isoforms [A p53β, p53γ, B Δ40p53α, Δ133p53α and Δ160p53α] or EV in controls (ctrl). Forty-eight hours after
transfection, cells were either mock- or MMC-treated (3 μM, 45min, 3 h release), subsequently cells were lysed with either lysis buffer for
protein extraction (50 mM Tris [pH7.4], 150mM NaCl, 2 mM EGTA, 2mM EDTA, 25mM Sodium fluoride, 25mM β-Glycerol phosphate, 0.1 mM
Sodium vanadate, 0.2% Triton X-100, 0.3 % Nonidet P40, complete protease inhibitor [Roche]) or IP lysis buffer (50mM Tris-HCl [pH 8], 150mM
NaCl, 1% NP40, complete protease inhibitor [Roche]) and then processed for immunoblotting using ubiquityl PCNA (Lys164, D5C7P, Cell
Signaling, Massachusetts, USA) antibody, recognizing PCNA protein only when ubiquitinated at Lys164, as well as antibodies against PCNA
and p53. β-Actin was used as loading control. “ub” indicates ubiquitination. Quantification of respective protein expression level was carried
out using ImageLab software. Levels of PCNA mono-/polyubiquitination were corrected for PCNA and normalized to ctrl (C, D) which was set
to 1 on each blot. Statistically significant differences among groups were calculated by Friedman test followed by Wilcoxon-signed ranks test
in case of statistical significance. Representative Western Blots from cells expressing ctrl, p53α, and C-terminal isoforms (A) or cells expressing
ctrl, p53α, and ΔN-isoforms (B). Heatmap of mean values from ≥ 5 independent experiments (C) or ≥ 4 independent experiments (D).
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Alternative p53-isoforms show loss-of-function in the p53-
POLι–dependent DDT-pathway mediating homology-directed
bypass of replication barriers
Treatment with MMC causes DNA intra- and interstrand-crosslinks,
which represent the ultimate roadblock for nascent DNA synthesis
[34, 35]. The p53-POLι-dependent DDT-pathway can overcome
these obstacles [20]. Hallmarks of this pathway, namely (i)
deceleration of DNA replication, (ii) increased POLι-foci assembly
and PCNA-POLι-co-localization, as well as (iii) PCNA-ubiquitination
were absent in cells expressing alternative p53-isoforms after
Y. Guo et al.
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MMC-treatment. Yet, under unperturbed growth conditions, these
key functions were retained at least partially. Another hallmark,
namely replication-associated recombination was undetectable
even in untreated cells expressing alternative p53-isoforms. Such
sensitive detection of loss-of-function can be explained because
this approach selectively identifies homology-directed bypass at
hard-to-replicate sites including extended secondary structures or
DNA-crosslinks stemming from naturally occurring aldehydes
[21, 36]. For comparison, DNA Fiber Spreading Assays reflect
nascent DNA synthesis at each progressing replication fork all over
the genome irrespective of a barrier, why enforced replication
stress is required to uncover defects.
Since alternative p53-isoforms still promoted DNA replication
slow-down and PCNA-POLι-co-localization under unperturbed
conditions, we conclude that alternative p53-isoforms can build
p53-PCNA-POLι-complexes at replication sites at least condition-
ally. Interestingly, these intermediate DDT-pathway defects
originate from different combinations of deficiencies and profi-
ciencies of key biochemical activities linked with specific protein
domains (Fig. 8). In case of C-terminal p53-isoforms, both p53β
and p53γ possess an intact N-terminus and consequently still
interacted with PCNA and partially with POLι in immunoprecipita-
tion experiments [20]. p53β and p53γ also possess an intact DBD
[23] and retain the interaction site with topoisomerase-I (aa 302-
321 [37]), another critical interaction partner in the pathway
[20, 25]. However, they lost half of the OD, which is required to
enhance binding to three-way DNA junctions in the tetramer
conformation [38] and accordingly to trigger p53-POLι-dependent
DDT [20]. p53β was reported to still bind DNA, however, in a
dimeric conformation [39]. We propose that C-terminal p53-
isoforms are transiently recruited to replication sites via physical
interactions with DDT factors. This may suffice to promote PCNA-
ubiquitination (a pre-requisite for DDT [40]) and deceleration of
nascent DNA synthesis under unperturbed conditions, but no
longer when MMC-roadblocks require tight association to DNA.
The ΔN-isoforms possess an intact OD and more than two-thirds
of the DBD. They are completely devoid of the PCNA and POLι
interaction sites within the N-terminal 40 aa of p53α [20, 41].
Consistently, we observed that Δ40p53α was defective in co-
immunoprecipitating these two proteins. ΔN-isoforms can no longer
contact the basal transcription machinery through the TAD I [42]. As
a transcriptional activator, p53 prominently upregulates p21 and
MDM2 [43–45], i.e., two proteins, which exhibit p53-independent
functions in DNA replication [29, 30, 46]. Here, we confirmed
reduced p21 and MDM2 levels in cells expressing alternative p53-
isoforms, particularly in p53γ, Δ133p53α, and Δ160p53α-expressing
cells. However, re-expression of p21 and MDM2 did not rescue
deceleration of nascent DNA synthesis, excluding that the p53 target
gene products are the missing components in cells expressing
alternative p53-isoforms.
Fig. 6 Co-expression of p53 isoforms affects the POLι-dependent DDT pathway. K562 cells were transfected with a total amount of 10 μg
plasmid DNA, containing either EV only in controls (ctrl) or expression plasmid for p53α plus EV (p53α+ EV) or for p53α plus p53α (p53α+
p53α) or for p53α plus one of the alternative isoforms (p53α+ p53β, p53α+ p53γ, p53α+Δ40p53α, p53α+Δ133p53α, and p53α+
Δ160p53α). For graphic presentation, calculation of SEM and statistically significant differences via Dunn’s multiple comparison test
GraphPadPrism8.4 software was used. # indicates a statistically significant difference between ctrl and the respective p53-isoform values. *(#)P
< 0.05, **(# #)P < 0.01, ***(# # #)P < 0.001, ****P(# # # #) < 0.0001. A, B: DNA fiber-spreading assays were performed 48 h after transfection. The
experimental design was as described in the legend to Fig. 2. Both mock-treated CldU- and IdU-tracks were measured but for clarity graphic
presentations focus on IdU-tracks in ongoing forks (≥421 fibers (A) and ≥320 fibers (B) in two independent biological experiments). POLι
(C), PCNA (D), POLι-PCNA colocalization (E) foci fold changes in K562 cells revealed by immunofluorescence microscopy. Mean values of p53α
+ p53α expressing and MMC-treated samples were set to 1 [on average 103 POLι (C), 133 PCNA (D), 15 POLι-PCNA colocalization (E) foci per
nucleus]. Experiments were performed together with the ones shown in Fig. 3. (F) Western blots for co-expression of p53 isoforms. Co-
expression of p53α and C-terminal isoforms were detected by anti-p53 antibody DO-1 (mouse, 554293, BD Biosciences, Franklin Lakes, New
Jersey, USA). Co-expression of p53α and ΔN-terminal isoforms were detected by anti-p53 antibody DO-11 (mouse, GTX75258, Genetex, Irvine
California, USA).
Fig. 7 Knockdown of endogenous p53-isoforms induces changes in fiber track lengths. U2OS cells (A) or HSPCs (B) were transfected with
nonsense siRNA (sictrl), siRNA targeting all p53-isoforms (sip53) or siRNA targeting Δ133p53/Δ160p53 isoforms (siΔ133p53). A, B: 24 h after
transfection, cells were sequentially incubated with CldU (20 µM) and IdU (200 µM) for 20min. During IdU-incorporation, cells were either
mock-treated or treated with 3 µM MMC. Both CldU- and IdU-tracks were measured while only IdU-tracks in ongoing forks (≥257 fibers from
two independent biological experiments) are graphically presented for clarity. Knockdown of p53-isoforms was verified by immunoblot
staining using anti-p53 (DO-11, MCA1704, Biorad) shown in the right panel of (A, B) each. Quantification of Δ133p53α relative to α-Tubulin
levels was achieved by Imagelab and is indicated above the blots. The dashed frame in (A) marks an unspecific band stained by DO-11 in
U2OS cells that had to be cut out, followed by antibody reincubation and a long exposure for 300 s to permit immunodetection of the
Δ133p53α-band. Statistically significant differences between groups were calculated by Dunn’s multiple comparisons test. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001.
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The p53-isoforms Δ133p53α and Δ160p53α were special in that
they showed signs of a replication defect already under
unperturbed conditions. Thus, we noticed increased replication
fork stalling (RFS) in the presence of these p53-isoforms to the
extent elicited by MMC-treatment. Shortening of DNA tracks can
be explained by exonucleolytic degradation, continuous slow-
down of DNA synthesis or by RFS [19]. We, therefore, propose that
replication deceleration observed in cells expressing Δ133p53α
and Δ160p53α is due to increased RFS and not due to p53α-POLι-
dependent DDT [19]. As this pathway is inactive in cells expressing
exonuclease-deficient p53(H115N) [47], it was proposed that p53-
POLι complexes slow down DNA synthesis via iterative idling that
gives time for HLTF-mediated PCNA-polyubiquitination and
ZRANB3-mediated fork reversal, i.e., homology-directed bypass
of the barrier [19]. Compatible with loss of idling, Δ133p53α and
Δ160p53α not only lack the N-terminal PCNA- and POLι-
interaction site, but additionally and distinct from Δ40p53α, the
binding site (aa 38-58) for human single-stranded DNA-binding
protein RPA [9, 48] and parts of the DBD enabling specific
recognition and exonucleolytic attack of three-way junctions
[11, 38]. Given the propensity of Δ133p53α and Δ160p53α to form
aggregates [39], it is conceivable that these p53-isoforms non-
productively occupy DNA replication sites through the residual
DBD and OD supported by the C-terminus recognizing DNA
lesions [10, 49] and by interacting with topoisomerase I [37, 50]
and PARylated PARP1 [51]. In support of the view that Δ133p53α
and Δ160p53α interact with replication forks, we noticed an
increase of PCNA foci without a concomitant rise in POLι-PCNA
Fig. 8 Model for the impact of different p53 isoforms on POLι-dependent DDT. A Hetero-oligomerization or aggregation of p53α with
alternative p53 isoforms, particularly with p53α+Δ133p53α or p53α+Δ160p53α, can antagonize p53α functions in the POLι-dependent
DDT. B C-terminal p53 isoforms still interact with PCNA [20, 41] but are compromised in binding to three-stranded DNA junctions like
replication forks due to shortened OD [38]. Intact DBD, OD, and RPA-interaction sites [8], but compromised interactions with POLι and PCNA
due to lack of the N-terminal end in Δ40p53α permit limited replication fork recognition only. Δ133p53α or Δ160p53α are compromised in
DNA-binding due to the N-terminally truncated DBD and in RPA-, POLι and PCNA-binding due to the missing N-terminus. However, all
N-terminal p53 isoforms retain the OD, enabling hetero-oligomerization with p53α and therefore dominant-negative interference with p53α
functions in performing idling events in complex with POLι and PCNA, giving time for PCNA ubiquitination and FR events by HLTF and
ZRANB3 [19]. Black arrows, DNA-binding; blue arrows, PCNA-binding; stippled arrow, compromised interaction.
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colocalizing foci. Additionally, Δ133p53α and Δ160p53α can no
longer compete for RPA70 subunit-binding with other potentially
harmful proteins such as the nuclease MRE11, known to act on
stalled and deprotected forks [19, 52–55].
Altogether, p53β, p53γ and Δ40p53α display residual perfor-
mance in the p53-POLι-dependent DDT-pathway, as at least one
of the underlying biochemical activities are retained each (Fig. 8).
However, Δ133p53α and Δ160p53α, with full proficiency to form
tetramers, but devoid of regions providing specificity for this DDT-
pathway cause non-specific deceleration of DNA replication
by RFS.
Alternative p53-isoforms exert an inhibitory effect in the
p53α-POLι-dependent DDT-pathway, which impacts on tumor
suppressor functions
Mutant p53 proteins were described to experience loss-of-
function, acquire gain-of-function and interfere dominant-
negatively with canonical and non-canonical wild-type p53
functions through hetero-oligomerization and aggregation
[56–60]. Squelching out of factors required for wild-type p53
function represents even one further dominant-negative mechan-
ism. In this work we found three pieces of evidence indicating
inhibitory effects of alternative p53-isoforms. First, all alternative
isoforms abrogated DNA replication slow-down by p53α under
unperturbed conditions. Second, Δ133p53α and Δ160p53α
elongated DNA tracks after ectopic co-expression with p53α in
tumor cells. Third, silencing endogenous Δ133p53/
Δ160p53 shortened tracks in MMC-treated HSPCs.
A dominant-negative effect of ΔN-isoforms with intact OD could
be explained by the formation of mixed hetero-oligomers with
less specific DNA-binding properties [32], as the N-terminal TAD of
p53 is known to directly interact with the DBD promoting specific
DNA interactions [61]. Having shown that Δ133p53α and
Δ160p53α cause RFS already on their own, we propose that these
ΔN-isoforms additionally squelch out C-terminal p53α-interaction
partners.
Accumulating evidence has shown that an increased ratio of
ΔN-isoforms/p53α is associated with poorer overall survival or
cancer aggressiveness, particularly for Δ133p53 in esophageal
squamous cell carcinoma [62], Cholangiocarcinoma [63], and
prostate cancer [64]. Here, we showed, that alternative p53-
isoforms, Δ133p53α and Δ160p53α, in particular, interfere with co-
expressed p53α in DDT. Since homology-directed DDT-pathways,
involving HLTF- and ZRANB3-mediated fork reversal, protect the
genome from unrestrained and mutagenic bypass mechanisms
like TLS [65, 66], we anticipate that these isoforms increase
genomic instability. Besides, the same ΔN-isoforms stimulate
proliferation and inhibit apoptosis [15, 23], all-in-all creating a
dangerous combination of pro-mutagenic and pro-survival
features, known to drive carcinogenesis. Intriguingly, p53α
evolved from N-terminally truncated Δ40p53α [15]. Hence, p53
gained the N-terminus which is critical for its canonical transcrip-
tional activities but also for its non-canonical function in
regulating replication dynamics by interacting with PCNA and
POLι [20]. Therefore, our observations may serve to better
understand the role of p53-isoforms in cancer and stem cells
regarding the maintenance of human genome stability.
MATERIALS AND METHODS
Cell culture and drug treatment
K562 and K562(HR-EGFP/3′EGFP) cells were cultivated in RPMI1640 medium
(Gibco by Thermo Fisher Scientific, Waltham, Massachusetts, USA)
supplemented with 13% FBS (Merck Millipore Darmstadt, Germany) and
1.3% Penicillin-Streptomycin-Glutamine (Gibco by Thermo Fisher Scientific,
Waltham, Massachusetts, USA). Saos-2 cells were cultivated in McCoy’s 5A
(Modified) Medium (Gibco by Thermo Fisher Scientific, Waltham,
Massachusetts, USA) or DMEM medium supplemented with 10% FBS
(Merck Millipore Darmstadt, Germany) and 1% Penicillin-Streptomycin-
Glutamine (Gibco by Thermo Fisher Scientific, Waltham, Massachusetts,
USA). U2OS cells were cultured in DMEM Medium (Gibco by Thermo Fisher
Scientific, Waltham, Massachusetts, USA) supplemented with 10% FBS and
1% Penicillin-Streptomycin-Glutamine. For DNA crosslinker treatment cells
were washed, incubated with DNA crosslinker Mitomycin C (MMC) (Sigma-
Aldrich by Merck, Darmstadt, Germany) containing media at a final
concentration of 3 µM or mock-treated with the solvent H2O for 45min,
washed and re-incubated with fresh media for additional 3 h. Cell cultures
were free from mycoplasma contamination as verified by PCR. HSPCs were
isolated from cord blood samples and cultivated as described in [22, 67].
Recombination measurements
To measure recombination frequencies K562 cells with chromosomally
integrated recombination substrate, K562(HR-EGFP/3′EGFP) [24] were
subjected to electroporation with expression plasmids for p53α, p53β,
p53γ, Δ40p53α, Δ133p53α, and Δ160 or empty vector (ctrl) as detailed in
the Figure legends. Recombination frequencies were measured 72 h after
transfection by quantification of one million cells from EGFP-positive cells
within the life cell-population (SSC/FSC gate). Mean values of recombina-
tion frequencies of p53α expressing cells were set to one and absolute
mean frequencies are detailed in the Figure legends.
DNA fiber spreading assay
To measure DNA replication track lengths for assessment of replication
speed the DNA fiber spreading technique was performed as detailed in
[20]. CldU (5-Chloro-2-deoxyuridine, Sigma-Aldrich by Merck, Darmstadt,
Germany) was incorporated for 20 min. After washing, IdU (5-Iodo-2-
deoxyuridine, Sigma-Aldrich by Merck, Darmstadt, Germany) was
incorporated in ten times higher concentration for another 20 min.
During the IdU pulse, cells were either treated with MMC (3 µM, Sigma-
Aldrich by Merck, Darmstadt, Germany) or its solvent H2O. Then, cells
were washed, harvested, and resuspended in PBS. 2500 cells were put on
a slide, lysed with 6 μl of 0.5% SDS, 200 mM Tris–HCl, pH7.4, 50 mM
EDTA, and incubated at room temperature for 6 min. Afterwards, they
were tilted about 20° to allow DNA-spreading via gravity. Subsequently,
slides were covered with aluminum foil, air-dried for 6 min, fixed for
5 min with newly prepared 3:1 methanol:acetic acid, air-dried for 7 min,
and stored in 70% ethanol at 4 °C. Twenty-four hours later, the slides
were processed for denaturation/deproteination in 2.5 N HCl for 1 h,
followed by immunofluorescence staining and microscopy. To deter-
mine the speed of ongoing replication, the track lengths of bi-colored
forks (CldU: green and IdU: red) were measured in the microscopic
images using ImageJ. These track lengths in μm obtained during a
20 min pulse each reflect DNA replication fork speed, which can be
calculated with the formula: DNA replication fork speed (kb/min) = 2.59
(kb/μm) × track length (μm) ÷ pulse time (min) [20]. For clarity lengths of
the red IdU tracks are shown only. For fork asymmetry analysis, track
lengths of IdU-incorporation (red) departing from the same origin (CldU,
green) were measured and the respective fork asymmetries show the
ratio of longer tracks versus shorter track lengths.
Immunofluorescence staining
K562 cells were spun onto cytospin glass slides. Then pre-extraction (1 min)
was performed (300mM Sucrose, 50 mM NaCl, 20 mM HEPES (pH 7.4),
3 mM MgCl2, 1 mM EDTA, 0.5% (v/v) Triton X-100, H2O). Cells were fixed
with 3.7% formaldehyde in PBS 3 h after MMC-release. Permeabilization
was performed with 0.5% Triton X-100 (Sigma-Aldrich by Merck,
Darmstadt, Germany) for 12min at RT. Blocking unspecific binding sites
was performed by use of 5% goat serum in PBS for 1 h. Immunostaining for
1 h at 37 °C was performed with the primary antibodies anti-PCNA PC10
(mouse mAb PC10, #ab29 Abcam Cambridge, UK), anti-Polymerase ι
(rabbit, polyclonal, #PA5-29442, Thermo Fisher Scientific, Waltham,
Massachusetts, USA) and was followed by an incubation time of 45min
at 37 °C with the secondary antibodies AlexaFluor555 (anti-rabbit,
Invitrogen by Thermo Fisher Scientific, Waltham, Massachusetts, USA) or
AlexaFluor488 (anti-mouse, Invitrogen by Thermo Fisher Scientific,
Waltham, Massachusetts, USA). Immunofluorescence microscopy of
nuclear signals was performed with Keyence BZ-9000 microscope
(Keyence, Cologne, Germany). Automated quantification of foci was carried
out using BZ-II Analyzer software. Intensity threshold and minimal focus
size were maintained throughout one set of simultaneously treated and
processed samples, both when detecting single green or red foci.
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Immunofluorescence staining after DNA fiber spreading assays was
performed after blocking with 5% bovine serum albumin (BSA) for
45 min. Following primary antibodies were used: anti-BrdU for detection
of IdU (mouse, mAb, clone B44, #347580 BD BioScience, Franklin Lakes,
New Jersey, USA) and anti-BrdU for detection of CldU (rat, mAb, clone
BU1/75 [ICR1] Novus #NB500-169 Nordenstadt, Germany or Abcam
#ab6326 Cambridge, UK) and incubated at room temperature (RT) for
1 h. As secondary antibodies, AlexaFluor555 (anti-mouse, Invitrogen by
Thermo Fisher Scientific, Waltham, Massachusetts, USA) or AlexaFluor488
(anti-rat, Invitrogen by Thermo Fisher Scientific, Waltham, Massachu-
setts, USA) were used (incubation time: 45 min, RT). DNA fibers were
imaged with Keyence BZ-9000 microscope (Keyence, Neu-Isenburg,
Germany). DNA fiber track lengths were measured with BZ-II Analyzer
software or using FiJi (Fiji is just ImageJ) software [ImageJ Wiki,
Laboratory for Optical and Computational Instrumentation, University
of Wisconsin-Madison, Wisconsin, USA [68].
(Chromatin-Crosslink) co-immunoprecipitation and
expression analysis
To isolate nuclear extracts, cells were incubated for 12min with
cytoskeletal (CSK, 250 mM Sucrose, 25 mM KCl, 1 mM HEPES (pH 7.5),
1 mM EGTA, 1 mM MgCl2, H2O) buffer with freshly added protease-
inhibitors (1 mM phenylmethylsulfonylflouride (PMSF), 1 mM Na3VO4,
0.1 mM dithiothreitol (DTT), protease inhibitor cocktail [Roche, Basel,
Switzerland]). By adding 1% MeOH-free formaldehyde (Thermo Fisher
Scientific, Waltham, Massachusetts, USA) in PBS for 10min at RT
crosslinking was performed. To stop this reaction, 10 mM ice-cold glycine
was added. Cells were lysed for 15min on ice in RIPA buffer (10mM Tris-
HCl [pH 7.5], 25 mM sodium-fluoride, 20 mM sodium-chloride, 1% sodium-
deoxycholate, 1% Nonidet P40, 0.1% SDS, H2O; freshly added inhibitors:
1 mM PMSF, 1 mM Na3VO4, 0.1 mM DTT, protease inhibitor cocktail [Roche,
Basel, Switzerland]). For disruption, sonification was carried out in the
sonification water bath Sonorex (Bandelin electronic GmbH & Co. KG,
Berlin, Germany) at the following conditions: high power, 30 s on/30 s off
for 7.5 min, and three repeats of this procedure. After centrifugation, the
supernatant was used for immunoprecipitation either of p53 with
antibodies Pab421 (mouse, OP03, Calbiochem, Darmstadt, Germany) and
p53(Do11) (mouse, MCA1704, BioRad Laboratories, München, Germany) or
of PCNA with anti-PCNA (mouse, ab29, Abcam, Cambridge, UK) or of POLι
with anti-POL ι (rabbit, A301-304A, Bethyl, Montgomery, USA). Isotype
control was performed by using normal IgG (mouse, sc-2025, Santa Cruz
Biotechnology, Dallas, Texas, USA).
For normal co-immunoprecipitations, cells were lysed in 50 mM Tris, pH
8; 150 mM NaCl; 1% NP40; complete protease inhibitor (Roche, Basel,
Switzerland). Protein-extract and protein G Sepharose (PGS) were rotated
over night at 4 °C to remove components unspecifically binding to PGS.
In parallel, antibody-PGS mixtures were rotated at 4 °C. Afterwards,
protein-extracts were separated from PGS by centrifugation and the
supernatants were transferred to the antibody-PGS mixtures, followed by
rotation at 4 °C for an additional 3 h. After spin-down, precipitated
proteins were washed 5 times with lysis buffer and dissolved in SDS-PAGE
sample buffer. For Western blot analysis, protein extracts were separated
electrophoretically, transferred to membranes, and proteins were
immunodetected via chemiluminescence. To detect the protein of
interest the following antibodies were used: anti-MDM2 (mouse,
MABE281, Merck Millipore Darmstadt, Germany), anti-p21 (mouse,
556430, BD Biosciences, Franklin Lakes, New Jersey, USA), anti-p53 (DO-
1, mouse, 554293, BD Biosciences Franklin Lakes, New Jersey, USA), anti-
p53 (DO-11, mouse, GTX75258, Genetex, Irvine California, USA), anti-p53
(PAb421, rabbit, ab245685, Abcam Cambridge, UK), anti-POLι (rabbit,
A301-303A, Bethyl Montgomery, Texas, USA), anti-PCNA (mouse, ab29,
Abcam Cambridge, UK), anti-Ubiquityl-PCNA (rabbit, 134395, Cell
Signaling, Massachusetts, USA), anti-HLTF (Rabbit, ab183042, Abcam
Cambridge, UK), anti-ZRANB3 (Rabbit, 23111-1-AP, Proteintech, Manche-
ster, UK), anti-β actin antibody (mouse, sc-47778, Santa Cruz Biotechnol-
ogies, Dallas, Texas, USA), anti-alpha Tubulin antibody (mouse, ab7291,
Abcam Cambridge, UK). Chemiluminescence detection and quantification
of protein levels were carried out in the linear range using ImageLab
software on a ChemiDocMP System (BioRad Laboratories, München,
Germany). Values for the protein of interest were corrected with values of
the loading control.
Western blotting for expression analysis without immunoprecipitation
followed the protocols described in [19]. Conditions of protein expression
were based on preceding titration experiments to ensure comparable p53
levels.
Cell cycle and apoptosis analysis
Cell cycle distribution and apoptosis in K562 cells were analyzed as
described in [19].
Transfection
Plasmids were transiently introduced in K562 and K562(HR-EGFP/3′EGFP)
via electroporation (GenePulser Xcell, BioRad Laboratories, München,
Germany) as described in [19]. In Saos-2 and U2OS cells plasmids/siRNAs
were transiently introduced using Amaxa Cell Line Nucleofector Solution V
and Amaxa device: program D-24 for Saos-2, X-01 for U2OS (Lonza, Basel
Switzerland) [20]. Introduction of siRNAs into HSPC cells relied on Amaxa B
cell Nucleofector Solution and Amaxa device program U-08.
Plasmids and siRNAs
The vectors pcDNA-p53α, pcDNA-p53β, pcDNA-p53γ, pcDNA-Δ40p53α,
pcDNA-Δ133p53α, and pcDNA-Δ160p53α used in this study were
generated at the University of Dundee as described in ([16, 26]). pGEX-
4T MDM2 WT was a gift from Mien-Chie Hung (Addgene plasmid #16237;
http://n2t.net/addgene:16237; RRID:Addgene_16237) [69]. pcDNA3-HA p21
was a gift from Jaewhan Song (Addgene plasmid #78782; http://n2t.net/
addgene:78782; RRID:Addgene_78782) [70]. For knockdown experiments
of POLι, HLTF, and ZRANB3 we engaged two shRNA-expressing plasmids
each, which were previously established in [19]. To silence all p53-isoforms,
the following siRNAs were used: GACUCCAGUGGUAAUCUAC and GGA-
GAAUAUUUCACCCUUC, to target Δ133/Δ160p53: GGAGGUGCUUACGCAU-
GUU and CUUGUGCCCUGACUUUCAA.
Statistics
Graphic presentation of data, statistical analysis, calculation of mean
values, standard deviation, and standard error of the mean were
performed with GraphPadPrism8.4 software (San Diego, CA). For calcula-
tion of statistically significant differences in recombination measurements,
the Kruskal−Wallis test followed by Mann−Whitney two-tailed test was
used. For calculation of statistically significant differences in DNA fiber
spreading analysis and immunofluorescence experiments Dunns-multiple
comparison test was used. For calculation of statistically significant
differences in Western Blot analysis, ANOVA followed by paired t-test or
Friedmann test followed by Wilcoxon-matched pair signed-rank test
was used.
DATA AVAILABILITY
The datasets generated during and/or analyzed during the current study are available
from the corresponding authors upon request.
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